Sugi Predict

Sugi Predict / Compounds / SCHEMBL1241324

SCHEMBL1241324

SCHEMBL1241324

CC(C)(C)OC(=O)N1C[C@@H](O[Si](C)(C)C(C)(C)C)C[C@@H]1CO

nearest known ligand 0.42

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ NR1H2 P55055 1/20 0.42
▸ SRC P12931 8/20 0.39
▸ ABCB1 P08183 1/20 0.35
▸ MEN1 O00255 2/20 0.34
▸ KMT2A Q03164 2/20 0.34
▸ CHRM2 P08172 1/20 0.33
▸ CHRM1 P11229 1/20 0.33
▸ CHRM3 P20309 1/20 0.33
▸ ALDH1A1 P00352 2/20 0.32
▸ L3MBTL1 Q9Y468 1/20 0.32
▸ PARP1 P09874 1/20 0.32
▸ USP2 O75604 1/20 0.31
▸ SMN1; SMN2 Q16637 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2386707 1.00 NR1H2 (0.42) NR1H2SRCABCB1MEN1KMT2A
SCHEMBL21286125 1.00 NR1H2 (0.42) NR1H2SRCABCB1MEN1KMT2A
SCHEMBL1241323 1.00 NR1H2 (0.42) NR1H2SRCABCB1MEN1KMT2A
SCHEMBL19964151 1.00 NR1H2 (0.42) NR1H2SRCABCB1MEN1KMT2A
SCHEMBL142689 1.00 NR1H2 (0.42) NR1H2SRCABCB1MEN1KMT2A
SCHEMBL139880 1.00 NR1H2 (0.42) NR1H2SRCABCB1MEN1KMT2A
SCHEMBL20312947 1.00 NR1H2 (0.42) NR1H2SRCABCB1MEN1KMT2A
SCHEMBL1372634 1.00 NR1H2 (0.42) NR1H2SRCABCB1MEN1KMT2A
SCHEMBL30868937 0.97 NR1H2 (0.40) NR1H2SRCABCB1MEN1KMT2A
SCHEMBL6577745 0.92 NR1H2 (0.41) NR1H2SRCMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12448389-B2 BRM targeting compounds and associated methods of use PRELUDE THERAPEUTICS INCORPORATED (US) 2025-10-21 — — US disclosed
EP-4587127-A1 BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE Prelude Therapeutics Incorporated (US) 2025-07-23 — — EP disclosed
US-20240390340-A1 PYRROLIDINE KRAS INHIBITORS INCYTE CORP (US) 2024-11-28 — — US disclosed
WO-2024220532-A1 PYRROLIDINE KRAS INHIBITORS INCYTE CORPORATION (US) 2024-10-24 — — WO disclosed
US-20240165244-A1 BRM Targeting Compounds And Associated Methods Of Use PRELUDE THERAPEUTICS INCORPORATED 2024-05-23 — — US disclosed
US-20240101557-A1 FUSED TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS G12V MUTANTS INCYTE CORPORATION 2024-03-28 — — US disclosed
WO-2024059806-A1 BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE PRELUDE THERAPEUTICS INCORPORATED (US) 2024-03-21 — — WO disclosed
WO-2024015731-A1 FUSED TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS G12V MUTANTS INCYTE CORPORATION (US) 2024-01-18 — — WO disclosed
US-20230373999-A1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2023-11-23 — — US disclosed
EP-4240743-A1 BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE Prelude Therapeutics, Incorporated (US) 2023-09-13 — — EP disclosed
US-20120135946-A1 ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS ACHAOGEN, INC. (US) 2012-05-31 — — US disclosed
US-20120135945-A1 ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS ACHAOGEN, INC. (US) 2012-05-31 — — US disclosed
US-20120135948-A1 ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS ACHAOGEN, INC. (US) 2012-05-31 — — US disclosed
US-20110288041-A1 ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS ACHAOGEN, INC. (US) 2011-11-24 — — US disclosed
US-7977343-B2 Adenine derivatives MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2011-07-12 — — US disclosed
WO-2011016234-A1 PICOLINAMIDE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2011-02-10 — — WO disclosed
US-20100160352-A1 ADENINE DERIVATIVES MERCK PATENT GMBH (DE) 2010-06-24 — — US disclosed
US-20100099661-A1 ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS ACHAOGEN, INC. (US) 2010-04-22 — — US disclosed
EP-1912994-A1 ADENINE DERIVATIVES Merck Patent GmbH (DE) 2008-04-23 — — EP disclosed
WO-2007017069-A1 ADENINE DERIVATIVES MERCK PATENT GMBH (DE) 2007-02-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120135948-A1 ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS MRPL21, NQO2, QARS1 NR1H2 2294/4885SRC 4860/4885ABCB1 115/4885
US-20120135946-A1 ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS MRPL21, NQO2, QARS1 NR1H2 2337/4885SRC 4827/4885ABCB1 100/4885
US-20100160352-A1 ADENINE DERIVATIVES HSP90AA1, TRAP1, HSP90AB1 NR1H2 1011/4885SRC 2822/4885ABCB1 64/4885
US-20240165244-A1 BRM Targeting Compounds And Associated Methods Of Use ABCG2, BRIX1, MRPS28 NR1H2 276/4885SRC 1735/4885ABCB1 4/4885
US-20100099661-A1 ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS MRPL21, MRPL9, NQO2 NR1H2 1577/4885SRC 4805/4885ABCB1 154/4885
US-20240390340-A1 PYRROLIDINE KRAS INHIBITORS KRAS, NRAS, HRAS NR1H2 2168/4885SRC 2485/4885ABCB1 1089/4885
US-20120135945-A1 ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS MRPL21, NQO2, QARS1 NR1H2 2420/4885SRC 4828/4885ABCB1 108/4885
US-20240101557-A1 FUSED TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS G12V MUTANTS KRAS, NRAS, HRAS NR1H2 1035/4885SRC 2202/4885ABCB1 576/4885
US-20110288041-A1 ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS MRPL21, NQO2, QARS1 NR1H2 2192/4885SRC 4828/4885ABCB1 119/4885
US-12448389-B2 BRM targeting compounds and associated methods of use ADRM1, BRDT, RBX1 NR1H2 2591/4885SRC 942/4885ABCB1 1582/4885
US-20230373999-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS NR1H2 1539/4885SRC 628/4885ABCB1 797/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.